These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37041352)

  • 1. New depression drug zuranolone one step closer to FDA ruling.
    Carvalho T
    Nat Med; 2023 May; 29(5):1032-1033. PubMed ID: 37041352
    [No Abstract]   [Full Text] [Related]  

  • 2. Concerns That May Limit the Utility of Zuranolone.
    Prasad V; Allely D
    JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
    Arnaud A; Bonthapally V
    J Affect Disord; 2022 Mar; 301():445-447. PubMed ID: 35032505
    [No Abstract]   [Full Text] [Related]  

  • 4. Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?
    Pine DS
    Am J Psychiatry; 2023 Sep; 180(9):631-633. PubMed ID: 37654113
    [No Abstract]   [Full Text] [Related]  

  • 5. Zuranolone: First Approval.
    Heo YA
    Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-superiority of zuranolone (SAGE-217) at the longer-term.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2021 Aug; 291():329-330. PubMed ID: 34082218
    [No Abstract]   [Full Text] [Related]  

  • 7. Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2022 Sep; 313():149-150. PubMed ID: 35780962
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
    Bullock A; Gunduz-Bruce H; Zammit GK; Qin M; Li H; Sankoh AJ; Silber C; Kanes SJ; Jonas J; Doherty J
    Hum Psychopharmacol; 2022 Jan; 37(1):e2806. PubMed ID: 34352138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
    Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
    J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
    Bullock A; Kaul I; Li S; Silber C; Doherty J; Kanes SJ
    J Neurol Sci; 2021 Feb; 421():117277. PubMed ID: 33387701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Oral Drug Rapidly Treats Postpartum Depression.
    Slomski A
    JAMA; 2021 Sep; 326(9):800. PubMed ID: 34547091
    [No Abstract]   [Full Text] [Related]  

  • 14. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why did the FDA approve these advertisements?
    Oaks D
    PLoS Med; 2006 Feb; 3(2):e117; author reply e116. PubMed ID: 16492081
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug suicide risks prompt call for FDA action.
    Check E
    Nature; 2004 Feb; 427(6974):474. PubMed ID: 14765156
    [No Abstract]   [Full Text] [Related]  

  • 17. Doing nothing is doing something: primary care antidepressant treatment in the era of FDA boxed warnings.
    Lacy BW; Baron DA; Goin MK; Gross LS; Slaby AE; Sumner CR
    J Am Osteopath Assoc; 2013 Feb; 113(2):117-9. PubMed ID: 23412671
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA approves pharmacologic stress agent.
    Thompson CA
    Am J Health Syst Pharm; 2008 May; 65(10):890. PubMed ID: 18463333
    [No Abstract]   [Full Text] [Related]  

  • 19. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
    Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
    [No Abstract]   [Full Text] [Related]  

  • 20. Off label drug promotion.
    Body Posit; 1998 Oct; 11(10):11. PubMed ID: 11365909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.